Home \ Neurology \ Approaches to pharmacotherapy of vascular mild cognitive impairment in patients of different age groups

Approaches to pharmacotherapy of vascular moderate cognitive disorders in patients of various age groups

Authors:
V.V. ZAKHAROV1, A.I. FEDIN2, E.A. MKHITARYAN2,3

1I.M. Sechenov First Moscow State Medical University of the Russian Ministry of Health (Sechenov University), Moscow, Russia;
2N.I. Pirogov Russian National Research Medical University of the Russian Ministry of Health, Moscow, Russia;
3Russian Gerontology Research and Clinical Center of N.I. Pirogov Russian National Research Medical University of the Russian Ministry of Health, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2023, Vol. 123, No. 10

Abstract:
This article discusses the potential for pharmacotherapy for vascular mild cognitive impairment in various age groups. It presents the results of the double-blind, randomized clinical trial MEMO using the antioxidant and antihypoxant drug Mexidol. Using a battery of tests to assess cognitive function, the sequential administration of parenteral and oral Mexidol demonstrated high efficacy in each of the three groups analyzed: 40-60, 61-75, and 76-90 years. Mexidol demonstrated a high safety profile in all age groups.

Key words: vascular moderate cognitive impairment, chronic cerebral ischemia, antioxidants, Mexidol.

Read more To the library

Actual

Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)
Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)
Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
Reproduced drugs: Benefit ratio/risk
Reproduced drugs: Benefit ratio/risk
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
Arterial hypertension and cognitive disorders. The gaze of a neurologist
Arterial hypertension and cognitive disorders. The gaze of a neurologist
The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)
The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)
The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)

Actual

Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)
Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)
Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
Reproduced drugs: Benefit ratio/risk
Reproduced drugs: Benefit ratio/risk
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
Arterial hypertension and cognitive disorders. The gaze of a neurologist
Arterial hypertension and cognitive disorders. The gaze of a neurologist
The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)
The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)
The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com